Advanced oxidation protein products accelerate bone deterioration in aged rats

Experimental Gerontology

Volumn 50, Issue 1, 2014, Pages 64-71

  Zeng, Ji Huan ^a   Zhong, Zhao Ming ^a   Li, Xiao Dan ^b   Wu, Qian ^a   Zheng, Shuai ^a   Zhou, Jian ^a   Ye, Wen Bin ^a   Xie, Fang ^a   Wu, Xiu Hua ^a   Huang, Zhi Ping ^a   Chen, Jian Ting ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Aged rats; AOPPs; Bone deterioration; Oxidative stress; Senile osteoporosis

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ADVANCED OXIDATION PROTEIN PRODUCT; ALBUMINOID; ALKALINE PHOSPHATASE; APOCYNIN; BIOLOGICAL MARKER; RAT SERUM ALBUMIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG;

ACID PHOSPHATASE BLOOD LEVEL; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BONE DEFECT; BONE DENSITY; BONE DETERIORATION; BONE TISSUE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FEMUR; LUMBAR VERTEBRA; MALE; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; SENILE OSTEOPOROSIS; SPRAGUE DAWLEY RAT; TIBIA; UPREGULATION; VERTEBRA; VERTEBRA BODY;

AGED RATS; AOPPS; BONE DETERIORATION; OXIDATIVE STRESS; SENILE OSTEOPOROSIS;

ACETOPHENONES; ADVANCED OXIDATION PROTEIN PRODUCTS; AGING; ANIMALS; ANTIOXIDANTS; BIOLOGICAL MARKERS; BIOMECHANICAL PHENOMENA; BONE DENSITY; BONE REMODELING; ENZYME INHIBITORS; FEMUR; LUMBAR VERTEBRAE; MALE; NADPH OXIDASE; OSTEOPOROSIS; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; TIBIA;

EID: 84890681560     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2013.11.014     Document Type: Article

References (36)

1. Bouxsein M.L. Determinants of skeletal fragility. Best Pract. Res. Clin. Rheumatol. 2005, 19:897-911.
2. Bouxsein M.L., Boyd S.K., Christiansen B.A., Guldberg R.E., Jepsen K.J., Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J. Bone Miner. Res. 2010, 25:1468-1486.
3. Brandi M.L. Microarchitecture, the key to bone quality. Rheumatology (Oxford) 2009, 48(Suppl. 4):iv3-iv8.
4. Christenson R.H. Biochemical markers of bone metabolism: an overview. Clin. Biochem. 1997, 30:573-593.
5. Cummings S.R., Melton L.J. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002, 359:1761-1767.
6. Dempster D.W. Bone microarchitecture and strength. Osteoporos. Int. 2003, 14(Suppl. 5):S54-S56.
7. Duque G., Troen B.R. Understanding the mechanisms of senile osteoporosis: new facts for a major geriatric syndrome. J. Am. Geriatr. Soc. 2008, 56:935-941.
8. Eastell R., Yergey A.L., Vieira N.E., Cedel S.L., Kumar R., Riggs B.L. Interrelationship among vitamin D metabolism, true calcium absorption, parathyroid function, and age in women: evidence of an age-related intestinal resistance to 1,25-dihydroxyvitamin D action. J. Bone Miner. Res. 1991, 6:125-132.
9. Finkel T., Holbrook N.J. Oxidants, oxidative stress and the biology of ageing. Nature 2000, 408:239-247.
10. Guo Z.J., Niu H.X., Hou F.F., Zhang L., Fu N., Nagai R., Lu X., Chen B.H., Shan Y.X., Tian J.W., Nagaraj R.H., Xie D., Zhang X. Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid. Redox Signal. 2008, 10:1699-1712.
11. Hancock J.T., Desikan R., Neill S.J. Role of reactive oxygen species in cell signalling pathways. Biochem. Soc. Trans. 2001, 29:345-350.
12. Klima L., Kawecka-Jaszcz K., Stolarz-Skrzypek K., Menne J., Olszanecka A., Wojciechowska W., Bilo G., Czarnecka D. Advanced oxidation protein products' level in serum is positively correlated with intima-media thickness in carotid arteries. Eur. Heart J. 2012, 33:137-137.
13. Kocak H., Oner-Iyidogan Y., Gurdol F., Oner P., Suzme R., Esin D., Issever H. Advanced oxidation protein products in obese women: its relation to insulin resistance and resistin. Clin. Exp. Med. 2007, 7:173-178.
14. Komosinska-Vassev K., Olczyk P., Winsz-Szczotka K., Kuznik-Trocha K., Klimek K., Olczyk K. Age- and gender-related alteration in plasma advanced oxidation protein products (AOPP) and glycosaminoglycan (GAG) concentrations in physiological ageing. Clin. Chem. Lab. Med. 2012, 50:557-563.
15. Krzystek-Korpacka M., Neubauer K., Berdowska I., Boehm D., Zielinski B., Petryszyn P., Terlecki G., Paradowski L., Gamian A. Enhanced formation of advanced oxidation protein products in IBD. Inflamm Bowel Dis 2008, 14:794-802.
16. Lei Z., Xiaoying Z., Xingguo L. Ovariectomy-associated changes in bone mineral density and bone marrow haematopoiesis in rats. Int. J. Exp. Pathol. 2009, 90:512-519.
17. Liu S.X., Hou F.F., Guo Z.J., Nagai R., Zhang W.R., Liu Z.Q., Zhou Z.M., Zhou M., Xie D., Wang G.B., Zhang X. Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1156-1162.
18. Manolagas S.C. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr. Rev. 2010, 31(3):266-300. (Jun; Epub 2010 Jan 5). 10.1210/er.2009-0024.
19. Meyer J.W., Holland J.A., Ziegler L.M., Chang M.M., Beebe G., Schmitt M.E. Identification of a functional leukocyte-type NADPH oxidase in human endothelial cells: a potential atherogenic source of reactive oxygen species. Endothelium 1999, 7:11-22.
20. Mosekilde L., Vestergaard P., Rejnmark L. The pathogenesis, treatment and prevention of osteoporosis in men. Drugs 2013, 73:15-29.
21. Pietschmann P., Skalicky M., Kneissel M., Rauner M., Hofbauer G., Stupphann D., Viidik A. Bone structure and metabolism in a rodent model of male senile osteoporosis. Exp. Gerontol. 2007, 42:1099-1108.
22. Piwowar A., Knapik-Kordecka M., Warwas M. AOPP and its relations with selected markers of oxidative/antioxidative system in type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 2007, 77:188-192.
23. Raisz L.G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005, 115:3318-3325.
24. Sambrook P., Cooper C. Osteoporosis. Lancet 2006, 367:2010-2018.
25. Seno T., Inoue N., Gao D., Okuda M., Sumi Y., Matsui K., Yamada S., Hirata K.I., Kawashima S., Tawa R., Imajoh-Ohmi S., Sakurai H., Yokoyama M. Involvement of NADH/NADPH oxidase in human platelet ROS production. Thromb. Res. 2001, 103:399-409.
26. Sherman S.S., Tobin J.D., Hollis B.W., Gundberg C.M., Roy T.A., Plato C.C. Biochemical parameters associated with low bone density in healthy men and women. J. Bone Miner. Res. 1992, 7:1123-1130.
27. Shi X.Y., Hou F.F., Niu H.X., Wang G.B., Xie D., Guo Z.J., Zhou Z.M., Yang F., Tian J.W., Zhang X. Advanced oxidation protein products promote inflammation in diabetic kidney through activation of renal nicotinamide adenine dinucleotide phosphate oxidase. Endocrinology 2008, 149:1829-1839.
28. Szulc P., Garnero P., Munoz F., Marchand F., Delmas P.D. Cross-sectional evaluation of bone metabolism in men. J. Bone Miner. Res. 2001, 16:1642-1650.
29. Tenenhouse A., Joseph L., Kreiger N., Poliquin S., Murray T.M., Blondeau L., Berger C., Hanley D.A., Prior J.C. Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos. Int. 2000, 11:897-904.
30. Wei Y.H., Lee H.C. Oxidative stress, mitochondrial DNA mutation, and impairment of antioxidant enzymes in aging. Exp. Biol. Med. (Maywood) 2002, 227:671-682.
31. Wei X.F., Zhou Q.G., Hou F.F., Liu B.Y., Liang M. Advanced oxidation protein products induce mesangial cell perturbation through PKC-dependent activation of NADPH oxidase. Am. J. Physiol. Renal Physiol. 2009, 296:F427-F437.
32. Witko-Sarsat V., Friedlander M., Capeillere-Blandin C., Nguyen-Khoa T., Nguyen A.T., Zingraff J., Jungers P., Descamps-Latscha B. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996, 49:1304-1313.
33. Witko-Sarsat V., Friedlander M., Nguyen K.T., Capeillere-Blandin C., Nguyen A.T., Canteloup S., Dayer J.M., Jungers P., Drueke T., Descamps-Latscha B. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J. Immunol. 1998, 161:2524-2532.
34. Zhang Y.B., Zhong Z.M., Hou G., Jiang H., Chen J.T. Involvement of oxidative stress in age-related bone loss. J. Surg. Res. 2011, 169:e37-e42.
35. Zhong Z.M., Bai L., Chen J.T. Advanced oxidation protein products inhibit proliferation and differentiation of rat osteoblast-like cells via NF-kappaB pathway. Cell. Physiol. Biochem. 2009, 24:105-114.
36. Zhou L.L., Cao W., Xie C., Tian J., Zhou Z., Zhou Q., Zhu P., Li A., Liu Y., Miyata T., Hou F.F., Nie J. The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis. Kidney Int. 2012, 82:759-770.